================================================================================

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT

                       Pursuant to Section 13 or 15(d) of
                       the Securities Exchange Act of 1934

                Date of report (Date of earliest event reported):
                                 April 12, 2006

                           HEMISPHERX BIOPHARMA, INC.
               (Exact Name of Registrant as Specified in Charter)

          Delaware                      0-27072                  52-0845822
(State or Other Jurisdiction          (Commission               (IRS Employer
      of Incorporation)              File Number)            Identification No.)

              1617 JFK Boulevard, Philadelphia, Pennsylvania, 19103
          (Address of Principal Executive Offices, including Zip Code)

       Registrant's telephone number, including area code: (215) 988-0080

                                 Not Applicable
          (Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

|_|   ] Written communications pursuant to Rule 425 under the Securities Act (17
      CFR 230.425)

|_|   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
      240.14a-12)

|_|   Pre-commencement communications pursuant to Rule 14d-2(b) under the
      Exchange Act (17 CFR 240.14d-2(b))

|_|   Pre-commencement communications pursuant to Rule 13e-4(c) under the
      Exchange Act (17 CFR 240.13e-4(c))

================================================================================

<PAGE>

Item 1.01.   Entry into a Material Definitive Agreement.
Item 3.02.   Unregistered Sales of Equity Securities

On April 12, 2006, Hemispherx Biopharma, Inc. (the "Company") entered into a
Common Stock Purchase Agreement ("Purchase Agreement") with Fusion Capital Fund
II, LLC, ("Fusion Capital"). Pursuant to the terms of the Purchase Agreement,
Fusion Capital has agreed to purchase from the Company up to $50,000,000 of the
Company's common stock over a period of approximately twenty-five (25) months.
Pursuant to the terms of a Registration Rights Agreement, dated as of April 12,
2006, the Company agreed to file a registration statement (the "Registration
Statement") with the Securities and Exchange Commission on or before June 30,
2006 covering the shares which are issued to or may be issued to Fusion Capital
under the Purchase Agreement. Once the Registration Statement has been declared
effective, each trading day during the term of the Purchase Agreement the
Company has the right to sell to Fusion Capital up to $100,000 of the Company's
common stock at a purchase price equal to the lower of the lowest trade price of
Company's common stock on such date or the arithmetic average of the three
lowest closing trade prices of the Company's common stock during the immediately
preceding 12 trading day period. At the Company's option under certain
conditions, Fusion Capital can be required to purchase greater amounts of common
stock during a given period. In connection with entering into the Purchase
Agreement, the Company issued to Fusion Capital 321,751 shares of its common
stock. This offering was made pursuant to an exemption from registration
provided by Section 4(2) of the Securities Act of 1933, as amended.

The Company anticipates using the proceeds from this financing for general
corporate purposes.

A copy of the Common Stock Purchase Agreement is attached hereto as Exhibit
10.1, and a copy of the Registration Rights Agreement is attached hereto as
Exhibit 10.2.

<PAGE>

Item 9.01.   Financial Statements and Exhibits.

             (c) Exhibits:

                 10.1  Common Stock Purchase Agreement, dated April 12, 2006

                 10.2  Registration Rights Agreement, dated April 12, 2006

<PAGE>

                                   Signatures

      Pursuant to the requirements of the Securities Exchange Act of 1934, as
amended, the registrant has caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

Date:  April 12, 2006

                                                   HEMISPHERX BIOPHARMA, INC.

                                                   /s/ William A. Carter
                                                   --------------------------
                                                   William A. Carter, M.D.,
                                                   Chief Executive Officer
{"company-data": {"conformed-name": "HEMISPHERX BIOPHARMA INC", "cik": "0000946644", "assigned-sic": "2836", "irs-number": "520845822", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "001-13441", "film-number": "06756748"}, "business-address": {"street1": "1617 JFK BLVD #660", "street2": "ONE PENN CENTER", "city": "PHILADELPHIA", "state": "PA", "zip": "19104", "phone": "2159880080"}, "mail-address": {"street1": "1617 JFK BLVD", "street2": "ONE PENN CENTER", "city": "PHILADELPHIA", "state": "PA", "zip": "19103"}}
================================================================================

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT

                       Pursuant to Section 13 or 15(d) of
                       the Securities Exchange Act of 1934

                Date of report (Date of earliest event reported):
                                 April 12, 2006

                           HEMISPHERX BIOPHARMA, INC.
               (Exact Name of Registrant as Specified in Charter)

          Delaware                      0-27072                  52-0845822
(State or Other Jurisdiction          (Commission               (IRS Employer
      of Incorporation)              File Number)            Identification No.)

              1617 JFK Boulevard, Philadelphia, Pennsylvania, 19103
          (Address of Principal Executive Offices, including Zip Code)

       Registrant's telephone number, including area code: (215) 988-0080

                                 Not Applicable
          (Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

|_|   ] Written communications pursuant to Rule 425 under the Securities Act (17
      CFR 230.425)

|_|   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
      240.14a-12)

|_|   Pre-commencement communications pursuant to Rule 14d-2(b) under the
      Exchange Act (17 CFR 240.14d-2(b))

|_|   Pre-commencement communications pursuant to Rule 13e-4(c) under the
      Exchange Act (17 CFR 240.13e-4(c))

================================================================================
Item 1.01.   Entry into a Material Definitive Agreement.
Item 3.02.   Unregistered Sales of Equity Securities

On April 12, 2006, Hemispherx Biopharma, Inc. (the "Company") entered into a
Common Stock Purchase Agreement ("Purchase Agreement") with Fusion Capital Fund
II, LLC, ("Fusion Capital"). Pursuant to the terms of the Purchase Agreement,
Fusion Capital has agreed to purchase from the Company up to $50,000,000 of the
Company's common stock over a period of approximately twenty-five (25) months.
Pursuant to the terms of a Registration Rights Agreement, dated as of April 12,
2006, the Company agreed to file a registration statement (the "Registration
Statement") with the Securities and Exchange Commission on or before June 30,
2006 covering the shares which are issued to or may be issued to Fusion Capital
under the Purchase Agreement. Once the Registration Statement has been declared
effective, each trading day during the term of the Purchase Agreement the
Company has the right to sell to Fusion Capital up to $100,000 of the Company's
common stock at a purchase price equal to the lower of the lowest trade price of
Company's common stock on such date or the arithmetic average of the three
lowest closing trade prices of the Company's common stock during the immediately
preceding 12 trading day period. At the Company's option under certain
conditions, Fusion Capital can be required to purchase greater amounts of common
stock during a given period. In connection with entering into the Purchase
Agreement, the Company issued to Fusion Capital 321,751 shares of its common
stock. This offering was made pursuant to an exemption from registration
provided by Section 4(2) of the Securities Act of 1933, as amended.

The Company anticipates using the proceeds from this financing for general
corporate purposes.

A copy of the Common Stock Purchase Agreement is attached hereto as Exhibit
10.1, and a copy of the Registration Rights Agreement is attached hereto as
Exhibit 10.2.
Item 9.01.   Financial Statements and Exhibits.

             (c) Exhibits:

                 10.1  Common Stock Purchase Agreement, dated April 12, 2006

                 10.2  Registration Rights Agreement, dated April 12, 2006
Signatures

      Pursuant to the requirements of the Securities Exchange Act of 1934, as
amended, the registrant has caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

Date:  April 12, 2006

                                                   HEMISPHERX BIOPHARMA, INC.

                                                   /s/ William A. Carter
                                                   --------------------------
                                                   William A. Carter, M.D.,
                                                   Chief Executive Officer